What is Phage Lab?
Phage Lab operates at the intersection of biotechnology and sustainable agriculture, specializing in the development of precision bacteriophage treatments. The company addresses the critical challenge of antibiotic overuse in livestock breeding processes. By utilizing a decade of collected epidemiological data, Phage Lab has engineered a platform capable of delivering personalized bacterial control solutions. Headquartered in Santiago, Chile, with an expanding footprint in Spain and Brazil, the company is effectively bridging the gap between advanced genomic research and practical, large-scale agricultural applications.
How much funding has Phage Lab raised?
Phage Lab has raised a total of $11M across 1 funding round:
Other Financing Round
$11M
Other Financing Round (2024): $11M with participation from Nazca and Collaborative Fund
Key Investors in Phage Lab
Nazca
Gruppo Nazca specializes in integrated solutions for Facility Management, Property Management, and Space as a Service, focusing on enhancing efficiency and innovation in building management.
Collaborative Fund
Collaborative Fund is a leading source of capital and strategic support for entrepreneurs, with a strong track record of backing transformative companies in the sustainability and consumer sectors.
What's next for Phage Lab?
With this latest infusion of capital, Phage Lab is poised to accelerate its international expansion and refine its diagnostic capabilities. The company's strategic roadmap likely involves deepening its market penetration in Brazil and Europe, where regulatory environments are increasingly favoring non-antibiotic bacterial management. By continuing to leverage its extensive epidemiological database, Phage Lab is well-positioned to transition from a specialized biotech innovator to a dominant force in global livestock health, ultimately setting a new standard for sustainable protein production and food safety.
See full Phage Lab company page
